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ABSTRACT The capsule is the dominant Streptococcus pneumoniae virulence factor,
yet how variation in capsule thickness is regulated is poorly understood. Here, we
describe an unexpected relationship between mutation of adcAII, which encodes a
zinc uptake lipoprotein, and capsule thickness. Partial deletion of adcAII in three of
five capsular serotypes frequently resulted in a mucoid phenotype that biochemical
analysis and electron microscopy of the D39 adcAII mutants confirmed was caused
by markedly increased capsule thickness. Compared to D39, the hyperencapsulated
adcAII mutant strain was more resistant to complement-mediated neutrophil killing
and was hypervirulent in mouse models of invasive infection. Transcriptome analysis
of D39 and the adcAII mutant identified major differences in transcription of
the Sp_0505-0508 locus, which encodes an SpnD39III (ST5556II) type I restriction-
modification system and allelic variation of which correlates with capsule thickness.
A PCR assay demonstrated close linkage of the SpnD39IIIC and F alleles with the hy-
perencapsulated adcAII strains. However, transformation of adcAII with fixed
SpnD39III alleles associated with normal capsule thickness did not revert the hyper-
encapsulated phenotype. Half of hyperencapsulated adcAII strains contained the
same single nucleotide polymorphism in the capsule locus gene cps2E, which is re-
quired for the initiation of capsule synthesis. These results provide further evidence
for the importance of the SpnD39III (ST5556II) type I restriction-modification system
for modulating capsule thickness and identified an unexpected linkage between
capsule thickness and mutation of adcAII. Further investigation will be needed to
characterize how mutation of adcAII affects SpnD39III (ST5556II) allele dominance
and results in the hyperencapsulated phenotype.
IMPORTANCE The Streptococcus pneumoniae capsule affects multiple interactions
with the host including contributing to colonization and immune evasion. During in-
fection, the capsule thickness varies, but the mechanisms regulating this are poorly
understood. We have identified an unsuspected relationship between mutation of
adcAII, a gene that encodes a zinc uptake lipoprotein, and capsule thickness. Muta-
tion of adcAII resulted in a striking hyperencapsulated phenotype, increased resis-
tance to complement-mediated neutrophil killing, and increased S. pneumoniae
virulence in mouse models of infection. Transcriptome and PCR analysis linked
the hyperencapsulated phenotype of the adcAII strain to specific alleles of the
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SpnD39III (ST5556II) type I restriction-modification system, a system which has previ-
ously been shown to affect capsule thickness. Our data provide further evidence for
the importance of the SpnD39III (ST5556II) type I restriction-modification system for
modulating capsule thickness and identify an unexpected link between capsule
thickness and adcAII, further investigation of which could further characterize
mechanisms of capsule regulation.
KEYWORDS Streptococcus pneumoniae, capsule expression, virulence, AdcAII,
restriction modification, SpnD39III
Streptococcus pneumoniae (the pneumococcus) is a Gram-positive bacterial commen-sal of the human nasopharynx (1) and also a common invasive pathogen causing
pneumonia, septicemia, and meningitis (2). S. pneumoniae has multiple virulence
factors which facilitate disease pathogenesis (3), the most important of which is the
capsule. The capsule is an extracellular polysaccharide layer which plays a crucial role
in S. pneumoniae immune evasion by inhibiting complement recognition, phagocytosis,
and bacterial entrapment by mucus (4). Variation in S. pneumoniae capsule structure
results in multiple different biochemical and antigen structures, with at least 98 distinct
capsule polysaccharide serotypes recognized at present (5). This diversity is mainly
related to genetic variation in the multigene cps locus (6) and correlates closely with
strain phenotypes such as invasive potential, duration of colonization, and ability to
evade complement-mediated neutrophil phagocytosis (7, 8). The degree of capsule
expression by S. pneumoniae is also affected by phase variation at different sites of
infection (9, 10). Opaque-phase S. pneumoniae has increased thickness of the capsule
layer and is associated with invasive infections such as septicemia, whereas
transparent-phase S. pneumoniae has thinner capsule layers and is associated with
colonization and biofilm formation (11–13). Despite the importance of capsule expres-
sion during S. pneumoniae interactions with the host, the molecular mechanisms
underpinning phase variation and capsule thickness remain relatively poorly under-
stood.
One mechanism that has been recently described to control capsule expression is
epigenetic regulation by phase-variable control of DNA methylation driven by the type
I restriction-modification system SpnD39III (ST5556II) (14). The SpnD39III (ST5556II)
system consists of multiple genes that can be shuffled by recombination on inverted
repeats to create enzymes capable of methylation at six different recognition sites.
Capsule expression and thickness (opaque versus transparent) have been correlated
with different SpnD39III alleles (14–16), and this system may be involved in regulating
at least some aspects of S. pneumoniae phase variation. As yet, both the environmental
conditions influencing allele distribution and how the effects of methylation patterns
on gene expression lead to changes in capsule thickness have not been resolved.
Within mammalian hosts, the available concentrations of several cations are strictly
controlled. As a consequence, cation ABC transporters of iron, manganese, and zinc are
essential for S. pneumoniae growth and survival in the host (17–19). ABC transporters
consist of a membrane-attached lipoprotein substrate binding protein and membrane
permease(s) and ATPase proteins. Zinc acquisition is mediated by two ABC transporters
identified by their lipoprotein components as AdcA and AdcAII (20, 21). Adjacent to
adcAII is phtD, which encodes the surface protein PhtD, a member of the Pht histidine
triad surface protein family that are involved in S. pneumoniae virulence. The histidine
triad motifs of Pht proteins have a high affinity for zinc, and these proteins may provide
a surface reservoir of zinc for import into S. pneumoniae via AdcA and AdcAII ABC
transporters (22–24). We have previously demonstrated that deletion of adcA partially
attenuates virulence, and deletion of both adcA and adcAII had a profound effect on S.
pneumoniae physiology under low zinc conditions and strongly attenuated virulence
(19, 25). In contrast, the virulence of the single adcAII deletion mutant was significantly
increased. Here, we describe this unexpected consequence of partial deletion of adcAII
in detail and show that the hypervirulence of the D39 adcAII mutant strains is
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associated with a mucoid phenotype and increased capsule expression and is corre-
lated closely with specific SpnD39III alleles and a point mutation in the csp2E capsule
locus gene.
RESULTS
Deletion of adcAII in the S. pneumoniae D39 strain results in a markedly
increased expression of the capsule. During our previous investigation of the func-
tional roles of the AdcA and AdcAII zinc ABC transporter systems, a single deletion
mutant of the adcAII gene was made by partial replacement of the adcAII gene with the
chloramphenicol resistance cassette cat (Fig. 1A). The resulting adcAII mutant strains
displayed a visibly increased mucoid colony morphology (Fig. 1B). Capsule thicknesses
FIG 1 Creation and macroscopic phenotype of the ΔadcAII mutant. (A) Gene map of the adcAII locus showing the
bp 201 to 750 deletion and replacement with an antibiotic resistance cassette (cat or kana) present in the ΔadcAII
mutant. (B) Colony morphology on Columbia blood agar plates of wild-type (WT) D39 strain and the ΔadcAII
mutant. (C) Relative amount of monosaccharides in capsule extracts of WT D39 strain and ΔadcAII mutant
determined by GC-MS. All monosaccharide derivatives were identified according to their specific retention times
and EI-MS fragmentations, as described in reference 26. (D) Example of measuring the volume of D39 and ΔadcAII
bacterial pellets using microcapillary tubes. (E) Height (mm) of bacterial pellets for the WT and mutant strains in
the indicated strains measured using microcapillary tubes. Each point represents data for independent clones
containing the indicated mutation, and bars represent mean values for independently derived colonies for each
mutant strain. P values were calculated using unpaired t test. **, P 0.01; ***, P 0.001.
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were compared between the D39 and adcAII mutant strains using a range of assays.
Initially, colony volume was assessed by transferring single colonies to a capillary tube
and measuring the height of visible bacterial material. This demonstrated an increased
volume of the adcAII strain compatible with a thicker capsule layer (Fig. 1D and E).
Capsule width was then directly visualized for the adcAII and wild-type D39 strains
using electron microscopy (EM), which demonstrated that the bacterial cells of the
adcAII mutant had a considerably enlarged capsule layer compared to D39 (Fig. 2A to
F). The mean capsule radius indicated that the ΔadcAII mutant expressed a capsule 5.6
times thicker than the wild-type (WT) D39 (capsule width of 61  1.8 nm versus 343 
8.3 nm for the D39 and ΔadcAII strains, respectively; n 30 for each strain). Monosac-
charide composition of capsule extracts for the ΔadcAII mutant and WT D39 strain
extracts were assessed biochemically using gas chromatography-mass spectrometry
(GC-MS). Total polysaccharide in capsule extracts demonstrated a 1.5-fold increase in
the ΔadcAII mutant compared to the wild-type strain, largely due to a 2-fold increase
in rhamnose content (Fig. 1C). Despite these changes in polysaccharide content, the
hyperencapsulated ΔadcAII strain was still recognized by serotype-specific antisera
(Fig. 2G to I). The small amount of GalNac detected was probably from teichoic acids
extracted with the capsular polysaccharide. Overall, these data demonstrated that
partial deletion of adcAII modified the polysaccharide content of the capsule with
overexpression of rhamnose-containing polysaccharides. To assess whether the ΔadcAII
mutant phenotype was serotype specific, additional ΔadcAII mutant strains were
obtained in capsular serotype 4, 6A, 6B, and 17F strains. Partial deletion of adcAII in the
6A and 6B serotypes also resulted in a mucoid phenotype suggestive of increased
capsule thickness but did not affect capsule thickness in the serotype 4 and 17F strains
(Fig. 1E).
FIG 2 Microscopic phenotype of the ΔadcAII mutant. (A, D, and G) Wild type. (B, E, and H) ΔadcAII
mutant. (C and F) ΔcpsD mutant. (I) R6 unencapsulated strain. (A to F) Electron microscopy of WT D39
strain and mutants, showing ultrathin sections of pneumococcus after capsule spring fixation using
lysine-acetate-based ruthenium red-osmium protocol. Scale bars and mean capsule width in nm (SD) are
given in the closeup views of selected examples of each strain in the right-hand column. (G to I) Confocal
microscopy of wild-type D39, R6, and ΔadcAII mutant strains showing the capsule in yellow (anti-type 2
capsule antibody and Alexa Fluor 546 anti-rabbit antibody) and DAPI in blue.
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Consistent association of the adcAII mutation with increased capsule expres-
sion by D39. To characterize further the relationship between partial deletion of adcAII
and increased capsule thickness, additional transformation and phenotyping experi-
ments were performed. Increased capsule expression was also detected in adcAII
strains made using the kanamycin resistance cassette kana instead of cat and if the
deletion included the immediate downstream gene (phtD) (Fig. 1E and Table 1).
Combined deletion of adcA and adcAII did not result in an increased capsule thickness
phenotype. When the adcAII mutation was created in an unencapsulated D39 strain
(ΔcpsD), colony volumes were similar to the parental strain and markedly lower than
with adcAII mutations in the WT D39 strain (Fig. 1E). The frequency with which
deletion of adcAII resulted in a strain with an increased capsule thickness was investi-
gated using multiple transformants made using the adcAII deletion constructs or by
transformation with genomic DNA extracted from a adcAII strain mutant. Of the 100
transformants, 44% (kana) or 42% (cat) had increased capsule thickness when trans-
formed with the PCR construct and 78% (18 out of 23) when transformed with genomic
DNA (Table 1). The remaining mutant clones either had a normal capsule thickness or
were unencapsulated. Growth of the adcAII strain in chemically defined medium
(CDM) supplemented with 33 M cations (Mn2 or Zn2), 5% sucrose, or recombinant
PhtD (50 g/ml) or in CDM depleted of cations by treatment with 1 mM EDTA did not
reduce increased capsule expression (data not shown; measured using capillary tube
colony volume). The increased capsule thickness phenotype was stable, with 100% of
100 colonies retaining a thick capsule after a single mucoid colony was cultured in THY
(Todd-Hewitt broth supplemented with yeast extract) liquid medium followed by
plating on blood agar plates over five generations. These data show that transforma-
tion of the S. pneumoniae D39 strain with a deletion construct affecting adcAII fre-
quently results in transformants with a marked increase in capsule quantity.
The hyperencapsulated D39 adcAII strain is resistant to complement-
mediated phagocytosis. The capsule is an essential virulence factor that prevents
opsonophagocytosis of S. pneumoniae but at a metabolic cost during S. pneumoniae
growth (7, 26). We therefore investigated the phenotypes of the hyperencapsulated
D39 adcAII strain in vitro and in murine infection models. Growth of the adcAII strain
was similar to the WT D39 in complete medium THY and in CDM (supplemented with
33 M zinc to overcome effects of loss of adcAII on zinc transport) (Fig. 3A and B). In
contrast, in blood approximately 1 log10 more adcAII bacteria were recovered after 4 h
of incubation compared to the D39 WT strain, with large differences in CFU persisting
at 6 h (Fig. 3C). Flow cytometry demonstrated increased resistance to opsonization with
complement and macrophage phagocytosis of the D39 adcAII strain compared to the
D39 WT strain (Fig. 4A to C). The D39 adcAII strain also had increased resistance to
killing by neutrophils compared to the WT strain; these differences were lost if bacteria
were opsonized in heat-treated (i.e., complement-deficient) sera or in phosphate-
buffered saline (PBS) alone, demonstrating that the differences were largely comple-
ment dependent (Fig. 4D). Adhesion assays showed there was no defect for the D39
adcAII strain in binding to the respiratory epithelium cell line Detroit 562 compared
to the WT strain (Fig. 5A). Hence, increased capsule expression by the adcAII strain was
TABLE 1 ΔadcAII mutant method of construction/source of DNA for the targeted deletion
related to the capsule phenotype for multiple transformants
DNA source for transformation
No. of clones
analyzed
Capsule phenotype
Absenta Normal Thick
PCR fragment adcAII::kana 100 14 (1) 32 44
PCR fragment adcAII::cat 100 45 (4) 13 42
Genomic DNA R6 ΔadcAII::cat1 1st 4 0 0 4
Genomic DNA R6 ΔadcAII::cat1 2nd 4 1 0 3
Genomic DNA R6 ΔadcAII::cat2 15 1 3 11
aNumbers in parentheses are numbers of absent capsule strains sequenced all of which contained the Q308
stop codon mutation in cps2E.
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associated with resistance to complement-mediated phagocytosis but did not inhibit
adhesion to a human nasopharyngeal cell line.
The hyperencapsulated adcAII strain has increased virulence. Both colony
forming units (CFU) in nasal washes at day 5 and competitive infection experiments
demonstrated that the hyperencapsulated D39 adcAII strain colonized the nasophar-
ynx to a similar degree as the WT D39 (Fig. 5B; Table 2), results which are consistent
with the lack of a difference between the strains for adhesion to Detroit 562 cells. In
contrast, the hyperencapsulated adcAII strain had increased virulence during systemic
or pneumonic infection. In competitive infection experiments using a sepsis model
(intraperitoneal [i.p.] inoculation), the D39 adcAII strain strongly outcompeted the WT
strain (Table 2), and in a murine sepsis model using pure inocula of each strain, 80% of
FIG 3 Growth phenotype of the WT D39 strain and ΔadcAII mutant. (A and B) Bacteria were inoculated
at an OD595 of 0.01 in THY (A) or CDM (B) supplemented with 33 M Zn and incubated at 37°C for 8 h.
Black circles, WT D39; white circles, ΔadcAII mutant. Two independent assays were performed using
triplicate wells. Each point is the mean (SD) for the results of a representative experiment. (C) Mean (SD)
WT D39 or ΔadcAII mutant CFU after culture in blood (1 ml inoculated with 1 106 CFU) for 4 and 6 h.
P values were calculated using unpaired Student’s t test. *, P 0.05.
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mice infected with the D39 adcAII strain progressed to fatal infection by 40 h
compared to 40% of mice infected with WT D39 (Fig. 6A). Finally, in a pneumonia model
higher CFU was recovered in both the lungs and blood from mice infected with the
adcAII mutant compared to wild-type D39 (Fig. 6B and C).
Transcriptome analysis of wild-type and hyperencapsulated adcAII strains. To
investigate mechanisms causing increased capsule production by the adcAII strain, a
transcriptome microarray analysis was performed on WT D39, one hyperencapsulated
adcAII and one adcAII/phtD strain clone, and one adcAII::cat unencapsulated clone
(Cl44) (Table 3). Three independent RNA extracts for each strain were submitted to
transcriptomic analysis. In total, 89 genes showed significant changes in expression
(1.5-fold, P 0.05) between the wild-type D39 and hyperencapsulated adcAII strain
(78 with reduced and 11 with increased expression in the mutant strain including the
deleted adcAII and downstream phtD genes), 96% (86/89) of which also showed
comparable changes in expression in the thick-capsule adcAII/phtD strain. In contrast,
11% (10/89) of these genes showed similar changes in expression in the Cl44 adcAII
strain without increased capsule expression, suggesting that the gene expression
changes were linked to the capsule phenotype. Expression of the D39 capsule locus
genes was not significantly different between the strains. Genes showing increased
expression in the hyperencapsulated adcAII and adcAII/phtD strains included genes
related to zinc uptake (adcR, adcA, phtA, and phtE), suggesting compensatory effects
FIG 4 The ΔadcAII mutant has increased resistance to complement and phagocytosis. (A) Mean fluorescence index
(MFI; measured in arbitrary units) of C3b/iC3b deposition on WT D39 or ΔadcAII mutant measured using flow
cytometry in 25% human serum. Error bars represent SDs. ***, P  0.001, unpaired t test. (B) Examples of flow
cytometry histograms for C3b/iC3b deposition on WT D39 or ΔadcAII mutant in 100% human serum. Gray shadowing
indicates the results for bacteria incubated in PBS alone. (C) Flow cytometry quantification of macrophage (THP-1
cells) phagocytosis of isothiocyanate fluorescein-labeled WT D39, R6 (unencapsulated derivative of D39), and the
ΔadcAII mutant for 1 h at 37°C (50 CFU/cell). The percentage of fluorescent macrophages was quantified by flow
cytometry, and the data are expressed as means (SD) of the percentage of the results for the WT D39 strain. **, P 
0.01, unpaired Student’s t tests. (D) Mean proportions of WT D39 (white columns) and the ΔadcAII mutant (black
columns) surviving incubation with fresh human neutrophils for 45 min (MOI of 500 bacteria/neutrophil). Data are
given for bacteria preincubated in PBS, 25% normal human serum, or 25% heat-inactivated human serum (no
complement activity). Error bars represent SDs, and P values were obtained using unpaired t tests.
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due to loss of the AdcAII zinc transporter. The other genes showing increased expres-
sion in the hyperencapsulated strains encode proteins of unknown function or con-
taining LysM domains predicted to be involved in cell wall metabolism (27). Three of
the operons that showed reduced expression in the hyperencapsulated strains are
predicted to be involved in pyrimidine synthesis: SPD_0608-09, encoding a predicted
orotate decarboxylase and phosphoribosyltransferase and being part of a larger operon
encompassing SPD_0608 to SPD_06187 (28); SPD_0851-52, predicted to encode a
dihydroorotate dehydrogenase electron transfer subunit (29); and SPD_1131, predicted
to encode a carbamoylphosphate synthase large subunit required for pyrimidine
synthesis from glutamine (30). Other genes showing reduced expression in the hyper-
encapsulated strains have roles in iron uptake (SPD_0224, -0226, and -1650), carbohy-
drate uptake (SPD_0279, 0362, 1050-1053, 1501, and 1987-95), and riboflavin synthesis
(SPD_0166-69). Of particular interest, the hyperencapsulated strains showed reduced
expression of SPD_0450, SPD_0452, and SPD_0453, creX (psrA), hdsS= (hsdS2), and hdsS
(hsdS1), from the SpnD39III (ST5556II) type I restriction-modification system, respec-
tively; this is discussed in detail below.
Increased capsule thickness of the adcAII strains correlated closely with
specific hsd alleles. The S. pneumoniae SpnD39III (ST5556II) type I restriction-modi-
fication locus undergoes genetic variation due to recombination within the locus
between pairs of inverted repeats, generating six allelic variants which are linked to
FIG 5 Effects of ΔadcAII on adhesion to epithelial cells. (A) Bacterial CFU recovered from the Detroit 562
cell adhesion assay (duration 1 h) with WT D39 or ΔadcAII mutant. There were no statistical differences
in CFU recovered for each strain (unpaired t tests). (B) WT D39 or ΔadcAII mutant CFU in nasal washes
recovered from mice 5 days after inoculation of either strain with 107 CFU under light halothane general
anesthesia. Each symbol represents data from a single mouse, bars represent medians, and error bars
represent the upper interquartile range. There were no statistically significant differences in nasal
wash CFU.
TABLE 2 Competitive index data for infection models using a mixed inoculum of 50% WT D39 and 50% D39 adcAII hyperencapsulated
strain
Infection model Inoculation route and CFU Sample source (time point) CI (SD) n P value
Nasopharyngeal colonization Intranasal, 5  106 CFU Nasal washes (5 days) 1.04 (0.15) 4 0.58
Sepsis Intraperitoneal, 5  104 CFU Blood (24 h) 4.6 (0.62) 7 0.0001
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opaque (increased capsule expression) and transparent (reduced capsule expression)
colony morphology (14–16). This suggests that the detected changes in expression of
genes within the SpnD39III (ST5556II) locus could reflect differences in the proportions
of the allelic variants between the WT and adcAII strains, and these differences could
underpin the hyperencapsulated phenotype of the latter. Hence, the proportion of
each of the six SpnD39III (ST5556II) variants was obtained for multiple individual
adcAII strains expressing either thick or normal-size capsules using a previously
described assay based on PCR followed by restriction digestion of the products (14)
(Table 4). This showed a clear correlation between capsule phenotype and the domi-
nant SpnD39III (ST5556II) variant. The WT D39 strain contained a mixture of the
SpnD39III (ST5556II) variants, mainly SpnD39IIIC with also a significant proportion of the
SpnD39IIID and F variants. With one exception, SpnD39IIIC (3 strains) and F (5 strains)
were the dominant variants found in the hyperencapsulated adcAII strains, whereas
SpnD39IIID (7 strains) or A (1 strain) was the dominant variant found in the adcAII
strains with normal capsule thickness. To try to link increased capsule formation by
some adcAII mutants to changes in the dominant alleles of the SpnD39III (ST5556II)
type I restriction-modification locus, the hyperencapsulated adcAII strain was trans-
formed with genomic DNA from D39 mutant strains with locked SpnD39III (ST5556II)
alleles due to an inactivated creX gene. Flow cytometry analysis of complement
sensitivity was used to rapidly assess capsular phenotype for 10 transformants for each
allele (A to F). All transformants retained the complement-resistant phenotype of the
hyperencapsulated adcAII strain, even those made using the SpnD39III (ST5556II)
alleles associated with a normal capsule width in adcAII transformants (A and D)
(Fig. 7), suggesting they all remained hyperencapsulated.
Genome sequence data for adcAII strains. Genome sequencing of one adcAII
and one adcAII/pht strain confirmed they contained the expected partial deletion of
adcAII or adcAII and phtD, respectively, with insertion of the antibiotic resistance
FIG 6 The ΔadcAII mutant has increased virulence in mouse models of sepsis and pneumonia. (A) For
the septicemia model, 5 104 CFU of each strain was injected intraperitoneally and the progress of
infection was followed over time. Empty circles represent data for the WT D39 strain, and filled black
circles show the ΔadcAII mutant strain. P values were obtained using the log rank test. (B and C) Blood
(B) and lung (C) CFU for the pneumonia model determined by plating serial dilutions on Columbia blood
agar recovered 48 h after infection for mice inoculated by intranasal instillation of 5 106 CFU. Each
symbol represents data from a single mouse, bars represent medians, and P values were calculated using
unpaired t tests. *, P  0.05.
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TABLE 3 Relative gene expression detected by microarray for genes showing statistically significant 1.5-fold differences in expression
for the thick-capsule adcAII AIIL strain compared to the WT D39 straina
Regulation status in
hyperencapsulated
strains and gene no. Gene name Predicted/known function
Mutant strain and capsule phenotype
adcAII (AIIL)
thick
adcAII/phtD
(AIIPcl4) thick
adcAII
(Cl44) none
Upregulated
SPD_0104 LysM domain protein 1.80 1.93 1.20
SPD_0389 accD Acetyl-CoA carboxylase subunit beta 1.55 1.59 	1.37
SPD_0646 Hypothetical protein 1.74 2.05 	1.18
SPD_0890 phtE Histidine triad protein 3.04 3.18 1.04
SPD_0891 Truncated histidine triad protein 3.25 1.16 1.37
SPD_0892 Truncated histidine triad protein 3.31 1.09 1.43
SPD_0893 Hypothetical protein 3.39 1.04 1.59
SPD_1038 phtA Histidine triad protein 1.98 1.52 	1.05
SPD_1874 LysM domain-containing protein 2.53 2.90 1.19
SPD_1997 adcA Zinc ABC transporter AdcA lipoprotein 1.52 1.41 1.03
SPD_2000 adcR adc operon repressor AdcR 1.55 1.65 	1.06
Downregulated
SPD_0052 purL Phosphoribosylformylglycinamidine synthase 	2.45 	2.36 1.24
SPD_0053 purF Amidophosphoribosyltransferase 	2.27 	2.34 1.25
SPD_0055 purN Phosphoribosylglycinamide formyltransferase 	2.13 	2.18 1.36
SPD_0090 ABC transporter lipoprotein 	2.02 	2.19 2.04
SPD_0166 ribH Riboflavin synthase, beta subunit 	2.76 	3.44 1.56
SPD_0167 ribB Riboflavin biosynthesis protein RibB 	2.51 	3.34 1.71
SPD_0168 ribE Riboflavin synthase subunit alpha 	2.52 	3.30 1.66
SPD_0169 ribD Riboflavin biosynthesis protein RibD 	2.40 	3.30 1.67
SPD_0224 pitD PitD iron ABC transporter permease 	2.28 	2.11 1.46
SPD_0226 pitA PitA iron ABC transporter lipoprotein 	2.01 	1.37 1.72
SPD_0265 adhP Alcohol dehydrogenase 	1.80 	1.83 1.63
SPD_0279 celB Cellobiose PTS system IIB component 	2.28 	1.79 1.76
SPD_0300 Oligohyaluronate lyase 	2.49 	1.60 1.32
SPD_0362 mtlF Mannitol PTS system IIA component 	2.38 	2.40 1.40
SPD_0364 Amino acid ABC transporter ATPase 	3.00 	2.80 1.84
SPD_0444 lytB Endo-beta-N-acetylglucosaminidase 	1.55 	1.69 1.38
SPD_0450 creX/psrA Type I restriction-modification system 3.39 4.24 1.43
SPD_0452 hsdS= (hsdS2) Type I restriction-modification system 3.62 6.41 1.25
SPD_0453 hsdS (hsdS1) Type I restriction-modification system 2.01 2.36 1.15
SPD_0466 blpT BlpT protein, fusion 	1.79 	2.26 1.52
SPD_0472 blpA ABC transporter, ATP-binding protein 	2.21 	3.47 1.59
SPD_0473 blpY Immunity protein BlpY 	1.50 	2.17 1.44
SPD_0553 Hypothetical protein 	1.59 	1.44 1.26
SPD_0595 Hypothetical protein 	1.55 	1.72 	0.64
SPD_0608 pyrF Orotidine 5=-phosphate decarboxylase 	1.65 	1.60 1.02
SPD_0609 pyrE Orotate phosphoribosyltransferase 	1.77 	1.67 1.02
SPD_0610 Hypothetical protein 	2.18 	2.26 1.45
SPD_0611 Hypothetical protein 	1.76 	1.94 1.19
SPD_0612 Hypothetical protein 	2.07 	2.06 1.00
SPD_0613 Hypothetical protein 	1.70 	1.83 1.09
SPD_0614 ABC transporter, ATP-binding protein 	1.76 	1.77 1.11
SPD_0615 ABC transporter substrate binding protein 	1.51 	2.25 1.25
SPD_0616 glnQ Amino acid ABC transporter ATPase 	1.56 	2.38 1.13
SPD_0617 glnP Amino acid ABC transporter permease 	1.76 	2.64 1.25
SPD_0618 glnP Amino acid ABC transporter permease 	1.71 	2.51 1.20
SPD_0851 pyrK Dihydroorotate dehydrogenase II 	1.90 	1.90 1.16
SPD_0852 pyrD Dihydroorotate dehydrogenase IB 	2.32 	2.28 1.11
SPD_0853 lytB Endo-beta-N-acetylglucosaminidase 	1.71 	1.65 1.09
SPD_0888 adcAII Zn2 ABC transporter lipoprotein 3.87 3.03 5.95
SPD_0889 phtD Hypothetical protein 1.78 2.50 4.2
SPD_1009 serB Phosphoserine phosphatase 	1.51 	1.24 1.60
SPD_1011 glxK Glycerate kinase 	1.63 	1.26 1.58
SPD_1035 PTS system, IIA component 	4.70 	4.83 	1.91
SPD_1036 PTS system, IIA component 	7.26 	5.84 	2.93
SPD_1050 lacD Tagatose 1,6-diphosphate aldolase 	1.61 	1.60 1.44
SPD_1051 lacC Tagatose-6-phosphate kinase 	1.62 	1.62 1.49
SPD_1052 lacB Galactose-6-phosphate isomerase LacB 	1.58 	1.56 1.46
(Continued on next page)
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cassette with no additional mutations elsewhere in the genome. Sequencing of the cps
locus in additional adcAII strains found that a nonsynonymous single nucleotide
polymorphism (SNP) affecting the capsule locus gene cps2E (E to K at amino acid 322)
was present in five out of 10 clones (Table 5), suggesting that this SNP may be relevant
for the hyperencapsulated phenotype at least for a proportion of adcAII strains.
However, the same SNP was also present in one of eight adcAII strains with normal
capsule thickness. All five of the unencapsulated adcAII strains investigated had cps2E
genes containing a stop codon at amino acid 308, which could explain their unencap-
sulated phenotype (Table 5).
DISCUSSION
In this work, we have described that mutation of the zinc transporter lipoprotein
gene adcAII in the S. pneumoniae D39 strain leads to an unexpected and striking
increase in capsule expression in 42% of the resulting mutants. This phenotype
occurred with adcAII mutations made by transformation either with a PCR construct
or with genomic DNA from another adcAIImutant and was stable over many bacterial
generations. A similar mucoid phenotype was also observed with the adcAII mutation
in two of the four other S. pneumoniae capsular serotypes investigated. The increased
capsule quantity was very marked, with EM showing a greater-than-5-fold increase in
capsule width and nuclear magnetic resonance (NMR) showing a 60% increase in the
quantity of monosaccharides in purified capsule. This level of increase in capsule
expression is markedly greater than that seen between opaque and transparent TIGR4
TABLE 3 (Continued)
Regulation status in
hyperencapsulated
strains and gene no. Gene name Predicted/known function
Mutant strain and capsule phenotype
adcAII (AIIL)
thick
adcAII/phtD
(AIIPcl4) thick
adcAII
(Cl44) none
SPD_1053 lacA Galactose-6-phosphate isomerase LacA 	1.61 	1.61 1.51
SPD_1074 metY O-Acetylhomoserine sulfhydrylase 	1.64 	1.92 1.51
SPD_1131 carB Carbamoylphosphate synthase subunit 	1.60 	1.37 1.06
SPD_1133 pyrB Aspartate carbamoyltransferase subunit 	1.51 	1.30 1.01
SPD_1175 Putative membrane protein 	1.68 	1.75 	1.43
SPD_1176 ABC transporter, ATP-binding protein 	1.69 	1.81 1.38
SPD_1177 Drug efflux ABC transporter 	1.73 	1.68 1.43
SPD_1178 ptrB Prolyl oligopeptidase family protein 	1.73 	1.78 	1.47
SPD_1179 Hypothetical protein 	1.74 	1.80 1.59
SPD_1454 Hypothetical protein 	1.56 	1.61 1.17
SPD_1455 Hypothetical protein 	1.84 	3.29 1.25
SPD_1498 Oxidoreductase 	2.21 	2.23 1.34
SPD_1501 Sugar ABC transporter permease 	3.73 	3.58 1.42
SPD_1503 Hypothetical protein 	3.25 	4.03 1.09
SPD_1513 Hypothetical protein 	1.77 	2.68 	1.40
SPD_1568 GTP cyclohydrolase 	1.80 	1.55 1.53
SPD_1584 ABC transporter permease 	2.30 	2.16 2.08
SPD_1650 fatC Iron uptake ABC transporter permease 	2.84 	2.23 1.30
SPD_1793 Universal stress protein family 	1.54 	1.74 2.00
SPD_1865 adh Zinc-containing alcohol dehydrogenase 	1.59 	1.28 1.48
SPD_1972 Hypothetical protein 	2.38 	2.96 1.75
SPD_1985 adh2 Iron-containing alcohol dehydrogenase 	2.05 	1.89 1.59
SPD_1987 Fucolectin-related protein 	3.12 	2.96 1.49
SPD_1989 PTS system, IID component 	2.19 	1.83 1.88
SPD_1990 PTS system, IIC component 	1.94 	1.74 1.60
SPD_1991 PTS system, IIB component 	1.83 	1.45 1.52
SPD_1992 PTS system, IIA component 	2.03 	1.79 1.68
SPD_1993 fucU Fucose operon FucU protein 	2.33 	2.10 1.83
SPD_1994 fucA L-Fuculose phosphate aldolase 	2.17 	2.33 1.63
SPD_1995 fcsK L-Fuculose kinase FucK, putative 	2.13 	2.07 2.12
SPD_2013 glpK Glycerol kinase 	2.76 	2.36 1.25
aFor comparison, the fold differences compared to WT D39 strain for the thick-capsule ΔadcAII/phtD strain (AII  Pcl14) and a normal-capsule-thickness ΔadcAII strain
(Cl144) are provided alongside. The adcAII, phtD, and SpnD39III (ST5556II) type I restriction-modification system genes are indicated in bold, and gene expression
profile differences in the ΔadcAII/phtD or the ΔadcAII (Cl144) compared to the ΔadcAII AIIL hyperencapsulated strain are indicated in italics. Abbreviations: CoA,
coenzyme A; PTS, phosphotransferase.
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capsular switched (less than 2-fold) (31) and 6B strains (32), justifying describing the
D39 adcAII strain as hyperencapsulated. The phenotypic consequence of the in-
creased capsule expression was a high degree of resistance to complement-mediated
immunity and hypervirulence in mouse models of pneumonia and sepsis. These
TABLE 4 Proportions of variants (identified by PCR analysis) for the SpnD39III (ST5556II)
type I restriction-modification system for selected adcAII mutant strains divided into
those with thick and normal capsule thicknesses
Phenotype Strain
Proportion (%) of SpnD39III (ST5556II) variant:
A B C D E F
Wild type D39 2.2 0 67.2 15.6 0 15.0
Thick capsule Cl82 1.3 0 3.8 7.1 1.0 86.8
Cl72 1.7 0 4.3 9.2 0 84.8
Cl10 1.3 0 4.0 8.8 0 85.9
Cl38 2.0 0 1.9 8.4 2.3 85.4
Cl3 2P 1.0 0 2.5 6.4 1.6 88.6
Cl5 1P 0.7 0 87.8 9.8 0 1.7
Cl3 1P 1.7 0 84.8 10.3 0 3.3
Cl1 1G 2.2 0 83.1 11.1 0 3.7
Cl7 1G 0 0 7.7 92.3 0 0
AIIL 3.8 0.6 74.9 17.8 0.0 2.8
Normal capsule Cl88 0 0 6.0 92.7 0.00 1.3
Cl28 0 0 6.7 93.3 0 0
Cl35 0 0 6.92 93.1 0 0
Cl6 0 0.7 5.71 93.6 0 0
Cl73 0 0 9.88 90.1 0 0
Cl20 0 0 9.93 90.1 0 0
Cl17 0 9.0 2.9 88.2 0 0
Cl1 0.4 1.7 16.4 80.8 0 0.6
Cl36 94.3 5.8 0 0 0 0
FIG 7 Flow cytometry analysis of complement sensitivity of the hyperencapsulated ΔadcAII strain after
transformation with locked SpnD39III (ST5556II) alleles (A to F) containing an inactivated creX gene.
ΔFP441, ΔFP442, ΔFP443, ΔFP444, ΔMRO559, and ΔMRO560 are all double mutant strains carrying the
adcAIImutation and an extra one in allele SpnIIIB, allele SpnIIIC, allele SpnIIIA, allele SpnIIID, allele SpnIIIE,
and allele SpnIIIF, respectively. (A) Fluorescence index (MFI measured in arbitrary units multiplied by
proportion of bacteria positive for C3b/iC3b) of C3b/iC3b deposition on ΔadcAII mutants and ΔadcAII
fixed SpnD39III allele transformants (alleles A to F) as a proportion of the fluorescence index for the
wild-type normal-capsule-thickness D39 strain. The data were measured using flow cytometry after
preincubation in 30% human serum. Error bars represent SDs, and 10 transformants were tested for each
double mutant strain. For all mutant strains, the P value for results compared to D39 was0.001
(unpaired t tests). (B) Examples of flow cytometry histograms for C3b/iC3b deposition on WT D39 (dark
gray line) and one ΔadcAII/SpnD39IIID allele (light gray line) double mutant transformant. Gray shading
indicates the results for bacteria incubated in PBS alone.
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phenotypes are exaggerated versions of the well-described effects of the capsule on S.
pneumoniae evasion of host immunity (7), demonstrating that under a normal level of
expression the capsule effects on immune evasion have not reached maximal potential.
Previous data have shown that capsule expression comes at a metabolic cost which
inhibits growth when cultured in defined medium and that the capsule prevents
adhesion by respiratory epithelium (26, 33, 34). However, surprisingly, these negative
aspects of capsule expression were not identified with the hyperencapsulated adcAII
strain. The serotype 2 S. pneumoniae capsule repeating unit is a hexasaccharide
consisting of one glucuronic acid, two glucoses, and three rhamnoses (6, 35). NMR
demonstrated that the relative proportion of glucose to rhamnose was altered in the
adcAII strain compared to WT D39, shifting from almost 1 to 1 in the latter to closer
to the expected 2-to-3 ratio. This would be compatible with an increased proportion of
the total S. pneumoniae glucose pool being used for capsule production. The larger
comparative increase in capsule width compared to changes in monosaccharide quan-
tity suggests the organization of the capsule may have been altered, perhaps with more
loosely packed but longer capsule strands in the adcAII strain compared to D39.
Why there is increased expression of the capsule in the adcAII strain is not clear.
The close linkage to adcAII suggests a role for disruption of zinc utilization, yet the
hyperencapsulated phenotype did not occur with mutation of the other S. pneumoniae
zinc uptake lipoprotein gene adcA (19) and was not affected by zinc availability.
Combined deletion of adcA and adcAII was also not associated with the hyperencap-
sulated phenotype, but the double mutation had major effects on S. pneumoniae
TABLE 5Mutation construction, capsule phenotype, and (where available) cps2E gene genome sequence data for S. pneumoniae strains
Strain/clone Gene deletion
Antibiotic
resistance Mutant construction Capsule ratio/D39 Capsule phenotype Mutation in cps2E
D39 800 None 1 Normal None
D39 WT None 1 Normal None
adcAIIL adcAII Cm New transformation 3.7 Thick None
Cl10 adcAII Kana New transformation 3 Thick E for K aaa 322
Cl57 adcAII Kana New transformation 0.5 Unencapsulated Stop codon aa 308
Cl1 1P adcAII Cm Back-crossing with adcAIIL 0.5 Unencapsulated Not sequenced
Cl1 1G adcAII Cm Back-crossing with adcAIIL 3 Thick Not sequenced
Cl1 1G adcAII Cm Back-crossing with adcAIIL 2.9 Thick None
Cl2 1P adcAII Cm Back-crossing with adcAIIL 0.5 Unencapsulated Not sequenced
Cl2 2P adcAII Cm Back-crossing with adcAIIL 0.9 Normal Not sequenced
Cl3 1G adcAII Cm Back-crossing with adcAIIL 3.1 Thick Not sequenced
Cl3 1P adcAII Cm Back-crossing with adcAIIL 3.2 Thick Not sequenced
Cl3 2P adcAII Cm Back-crossing with adcAIIL 3.1 Thick None
Cl5 1P adcAII Cm Back-crossing with adcAIIL 3.8 Thick None
Cl5 1G adcAII Cm Back-crossing with adcAIIL 3.7 Thick Not sequenced
Cl6 1P adcAII Cm Back-crossing with adcAIIL 0.5 Unencapsulated Not sequenced
Cl6 2P adcAII Cm Back-crossing with adcAIIL 0.5 Unencapsulated Stop codon aa 308
Cl7 1P adcAII Cm Back-crossing with adcAIIL 3.5 Thick Not sequenced
Cl7 1G adcAII Cm Back-crossing with adcAIIL 3.1 Thick None
AIIcl 1 adcAII Cm New transformation 1 Normal None
AIIcl 17 adcAII Cm New transformation 1.1 Normal None
AIIcl 20 adcAII Cm New transformation 1.1 Normal None
AIIcl 28 adcAII Cm New transformation 1.15 Normal None
AIIcl 31 adcAII Cm New transformation 0.5 Unencapsulated Stop codon aa 308
AIIcl 35 adcAII Cm New transformation 0.85 Unencapsulated Stop codon aa 308
AIIcl 36 adcAII Cm New transformation 1.05 Normal E for K aa 322
AIIcl 38 adcAII Cm New transformation 2.05 Thick E for K aa 322
AIIcl 44 adcAII Cm New transformation 0.5 Unencapsulated Stop codon aa 308
AIIcl 72 adcAII Cm New transformation 2.8 Thick E for K aa 322
AIIcl 73 adcAII Cm New transformation 1.15 Normal None
AIIcl 75 adcAII Cm New transformation 1.2 Normal None
AIIcl 78 adcAII Cm New transformation 1.8 Thick E for K aa 322
AIIcl 82 adcAII Cm New transformation 2.6 Thick E for K aa 322
AIIcl 88 adcAII Cm New transformation 1 Normal None
AIIPcl4 adcAII  phtD Cm New transformation 2.2 Thick Not sequenced
aaa, amino acid position.
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physiology (19) which could have obscured or suppressed the mucoid phenotype.
Overall regulation of S. pneumoniae capsule expression is poorly understood and is
further complicated by the large number of different capsular carbohydrate structures
with potentially significant differences in regulatory mechanisms. Factors affecting
thickness of the capsule layer include regulation of cps locus gene expression by RitR
(an orphan two-component signal transduction component) (36), CpsR (a GntR family
regulator) (37), and RegM (38), as well as the conserved 5= cpsABCD (also termed wzg,
wzh, wzd, and wze) genes of the cps locus (39–41). Two S. pneumoniae quorum-sensing
systems (LuxS/AI-2 and the Rgg/small hydrophobic peptide system) increase capsule
thickness (42–44), which can also be regulated independently of gene transcription by
the supply of capsule monosaccharide precursors (45) or by increased capsule shedding
mediated by LytA (12). However, our transcriptome analysis did not identify increased
cps locus gene expression or any effects on the abovementioned known regulators of
capsule expression in the adcAII strain.
Another potential mechanism causing the hyperencapsulated phenotype in the
adcAII mutant was identified by effects on transcription of the SPD_0450-0453 locus.
This encodes the SpnD39III (ST5556II) type I restriction-modification system, allelic
variants of which correlate with capsule thickness for several serotypes (14–16). We
found that the hyperencapsulated phenotype of adcAII mutants was associated with
a predominance of either the SpnD39IIIC or F allelic variant, whereas SpnD39IIID was
the dominant allele for the majority of adcAII mutants with normal capsule thickness.
This link between the hyperencapsulated phenotype of the adcAII strain and specific
alleles of the SpnD39III (ST5556II) system seems unlikely to be coincidental given the
known effects of this restriction-modification system on capsule expression. However,
transformation with fixed SpnD39III (ST5556II) alleles, including those associated with
normal capsule thickness (A and D), did not alter the hyperencapsulated phenotype of
the adcAII mutant, showing that any effects of SpnD39III alleles on the capsule
thickness of the adcAII mutation are not readily reversed by switching alleles. This
situation is further confused by the similarity in allele composition of the wild-type D39
strain and the AIIL adcAII mutant and by differences between our data and published
papers in which SpnD39III alleles are linked to thick or thin capsule phenotypes. Manso
et al. found that A, E, and F allele strains were largely opaque but C strains were more
transparent, Li et al. found that only E allele strains (termed hsdSa in their paper) were
opaque, and Oliver et al. found that the A and B alleles were opaque and the others
transparent (14–16). The presumed mechanism of capsule regulation by SpnD39III is
differential methylation of genes or regulatory regions (14, 15), but the genes involved
remain undetermined. Our transcriptome data have identified multiple additional
genes showing differential expression between hyperencapsulated adcAII strains and
wild-type D39 or a normal-capsule-width adcAII mutant, some of which could be
involved in mediating increased capsule expression. These include three operons
annotated as being involved in pyrimidine metabolism, suggesting a potential role for
pyrimidine in controlling capsule expression. Which genes showing differential expres-
sion between the adcAII strains and WT D39 strains are involved in the capsular
phenotype and whether differential regulation is related to differences in methylation
will require considerably more detailed genetic studies.
Interestingly, 50% of independently obtained hyperencapsulated adcAII strains
contained an identical nonsynonymous SNP affecting the cps locus gene csp2E. The SNP
is predicted to affect the cytoplasmic tail of Csp2E, a glucose phosphate transferase that
initiates the assembly of capsule components on the cell membrane and is partially
conserved among most capsular serotypes (39). Point mutations of cps2E that affect
capsule expression have been previously described (32, 39), suggesting a causative role
for this SNP for the adcAII-related capsule phenotypes. However, the same SNP was
not present in one lineage of adcAII with increased capsule thickness (the original
transformant and four back-crossed derivatives) and was also identified in one out of
eight normal-capsule-thickness adcAII strains. All the unencapsulated adcAII trans-
formants also contained the same SNP in csp2E predicted to introduce a stop codon.
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This high frequency of cspE2 stop codon mutations suggests that partial deletion of
adcAII causes significant physiology stress to S. pneumoniae that may induce loss of
capsule production as an escape mutation.
To conclude, we have identified that in the S. pneumoniae D39 strain a hyperen-
capsulated phenotype is an unexpected consequence of targeted mutation of adcAII,
which encodes a zinc ABC transporter lipoprotein. This strain will be a useful tool for
investigating how the capsule affects S. pneumoniae interactions with the host. The
hyperencapsulated phenotype partially correlated with both a nonsynonymous SNP in
cps2E and changes in allelic dominance within the SpnD39III (ST5556II) restriction-
modification system. Further investigation of genes showing differential expression
between normal and hyperencapsulated D39 strains could help to further identify the
underlying mechanism(s) controlling S. pneumoniae capsule thickness.
MATERIALS AND METHODS
Bacterial strains and growth conditions. The ΔadcAII, ΔphtD, ΔadcA/adcAII, and ΔadcAII/phtD
mutant strains were created either in the wild type or in the ΔcpsD D39 strain as well as in wild-type
serotype 4 (TIGR4), 6A, 6B (strains 6Aa and 6Ba, respectively, from the work of Hyams et al. [31]), and 17F
(46) strains by gene replacement using genomic DNA or PCR-amplified fragments obtained from the
corresponding R6 mutants and standard transformation protocols for S. pneumoniae (19). The cat and
kana genes were inserted in the reverse orientation without promoter or terminator sequences to avoid
affecting expression of adjacent genes. Mutant identities were verified by PCR with primers flanking the
cloned regions. S. pneumoniae was grown at 37°C with 5% CO2 in air in THY or on Columbia agar
containing 5% blood. Working stocks grown to an optical density (OD) of 0.4 (
108 CFU/ml) were made
using THY and stored at 	80°C in 10% glycerol as single-use aliquots. CFU were confirmed by colony
counting of log10 serial dilutions of bacteria cultured overnight on 5% Columbia blood agar. Growth
curves were determined by measuring OD595 for bacteria cultured in 2.5 ml of THY or chemically defined
medium (CDM) supplemented with 33 M Zn in 24-well plates sealed with a transparent film and
incubated at 37°C in a FLUOstar reader. To measure blood growth, 1 106 CFU/ml of S. pneumoniae was
inoculated into 1 ml of heparinized human blood and incubated at 37°C, with plating of serial dilutions
at 0, 4, and 6 h to assess bacterial CFU.
Capsule size measurement and microscopy. An indirect method was developed to measure
capsule size by determining the size of the bacterial pellet. Briefly, 12 ml of culture was centrifuged, the
pellet was resuspended in 120 l of PBS, and 35 l was loaded in a microcapillary tube. After
centrifugation for 15 min at 800  g, the height of the pellet within the tube was measured with a ruler.
Electron microscopy of mid-log-phase S. pneumoniae fixed in 3% paraformaldehyde (PAF) was performed
using a ruthenium red and London resin capsule-preserving protocol as previously described (33).
Capsule thickness was calculated by direct measurement of the surface layer for 30 randomly chosen S.
pneumoniae bacteria/strain using ImageJ software.
Confocal microscopy on bacteria was performed using an Olympus FV1000 confocal laser scanning
microscope with a 63 objective. Bacteria were fixed for 30 min with 4% PFA (Sigma) on slides (Thermo
Scientific; SuperFrost Plus 10149870) and subsequently stained with anti-serotype 2 antibody (Statens
Serum Institute) plus Alexa Fluor 546-conjugated anti-rabbit antibody. DNA was stained with 4=,6-
diamidino-2-phenylindole (DAPI).
Capsular polysaccharide extraction and quantification. Capsular polysaccharides were extracted
from 1 liter of culture, and bacteria were resuspended in 10 ml of 0.15 M Tris buffer (pH 8) supplemented
with 0.1% deoxycholate and incubated for 10 min at 37°C and then for 35 min at 50°C. Cell debris was
removed by centrifugation under acidic condition. Proteins were eliminated from the supernatant by two
successive extractions using a 5:1 ratio of chloroform and butanol, before precipitating capsular
polysaccharides in 80% ethanol. Pellets were dried, resuspended in 0.1 M phosphate buffer (pH 7.2), and
incubated with DNase and RNase for 1 h at 37°C, and then trypsin was added for 2 h at 37°C before
purification of capsular polysaccharide by ion exchange on a column of DEAE Sepharose. Monosaccha-
ride composition was established by GC and GC-MS as alditol acetate derivatives. Briefly, samples were
hydrolyzed in 4 M trifluoroacetic acid (TFA) for 4 h at 100°C and reduced with sodium borohydride in 0.05
M NaOH for 4 h. Reduction was stopped by dropwise addition of acetic acid until pH 6 was reached, and
borate salts were codistilled by repetitive evaporation in dry methanol. Peracetylation was performed in
acetic anhydride at 100°C for 2 h. All monosaccharide derivatives were identified according to their
specific retention times and electron ionization MS (EI-MS) fragmentation patterns (47).
Phagocytosis, neutrophil killing, complement deposition, and adhesion assays. Flow cytometry
phagocytosis and complement deposition assays were performed as previously described (7, 48) using
S. pneumoniae incubated for 30 min with human serum (25%), human heat-inactivated serum (25%), or
just Hanks balanced salt solution (HBSS) medium. For macrophage phagocytosis, THP-1 monocytes
cultured in suspension in RPMI medium supplemented with 10% fetal bovine serum (FBS) were treated
for 24 h with 10 nM phorbol 12-myristate 13-acetate (PMA) to induce cell adhesion and macrophage
differentiation. Flow cytometry was performed using a fluorescence-activated cell sorting (FACS) Verse
machine (BD), and the data were analyzed with FlowJo software. For neutrophil killing assays, fresh
human neutrophils were purified using a magnetically activated cell sorting (MACS) neutrophil isolation
kit (Miltenyi Biotec) and resuspended in HBSS medium at a concentration of 1 106 cells/ml. S.
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pneumoniae previously incubated with human sera was incubated with the neutrophils at a multiplicity
of infection (MOI) of 1:500 (bacteria to neutrophils) in a 48-well plate for 45 min at 37°C. Adhesion
assays were performed on Detroit 562 human nasopharyngeal cells (ATCC CCL-138) as previously
described (34, 49) using 3 105 cells/well seeded into 24-well plates, infected with MOIs of 25 and
50, and incubated for 1 h before being washed three times with PBS, followed by addition of
Dulbecco’s modified Eagle’s medium (d-MEM)-1% saponin for 10 min and plating of serial dilutions
to count bacterial CFU.
Genome sequencing and transcriptional microarray analysis. Mutant strains were genome
sequenced by the Wellcome Trust Centre for Human Genetics (Oxford, United Kingdom) using an
Illumina MiSeq sequencer. Sequences were assembled using Velvet, annotated using Prokka, and
mapped to the published D39 (R00000036) reference genome. Bases and single-nucleotide variants were
identified using the SAMtools “mpileup” command and Bcftools. Sites were filtered to a minimum depth
of five reads at each and a single-nucleotide variant quality of 25, and the Integrated Genome Viewer was
used to visualize mapping and coverage. Gene transcriptome microarrays were performed as described
previously (34). Briefly, RNA was extracted with the RNeasy minikit (Qiagen), and labeled cDNA was
prepared using Cy3-dCTP (GE Healthcare, United Kingdom) and SuperScript II reverse transcriptase with
random hexamer primers (Life Technologies). Labeled cDNA was hybridized overnight to the BG@S
SPv1.4.0 Agilent SurePrint platform (Agilent Technologies) microarray designed by the Bacterial Microar-
ray Group at St. George’s, University of London. After hybridization, washed slides were scanned
immediately, using an Agilent high-resolution microarray scanner, at 5-m resolution; scanned images
were quantified using Feature Extraction software v 10.7.3.1 (Agilent Technologies); and statistical
analysis of raw intensity data was performed in GeneSpring v14.9.1 (Agilent Technologies). Data for 3
independent biological replicate experiments were analyzed and normalized using a 75th percentile shift
plus baseline normalized to the median for the related control sample for each biological replicate.
Statistically significant (P 0.05) differences between strains were identified in an unpaired t test with
Benjamini and Hochberg false-discovery rate correction.
Assessing allelic variants of SpnD39III. Primers AMRE74L (5= 6-carboxyfluorescein [FAM] label,
FAM-GGAAACTGAGATATTTCGTGGTGATGATGGGA) and AMRE59 (CCTGATCGAGCGGAAGAATATTTCTGCC
GAGGTTGCC) were used to PCR amplify a 4.2-kb fragment from S. pneumoniae under the following
conditions: denaturation at 95°C for 5 min, followed by 40 cycles of 1 min of denaturation at 95°C, 1 min
of annealing at 68°C, and 5 min of extension at 68°C, with a final extension of 10 min at 68°C. PCR
products were digested using 1 U DraI, 2 U PleI, and 1 CutSmart Buffer (all from New England Biolabs,
United Kingdom) in a 20-l volume. Each FAM-labeled SpnIII variant has a unique size that can be
distinguished through capillary electrophoresis on an ABI Prism gene analyzer (Applied Biosystems, USA)
and analyzed using Peak Scanner v1.0 software. Genomic DNA for transformation using locked SpnD39III
(ST5556II) alleles due to an inactivated creX gene was obtained from preexisting strains (14).
Animal models of infection. All animal experiments conformed to institutional and United Kingdom
Home Office guidelines and regulations. Outbred CD1 sex-matched white mice were used for infection
experiments using established models of infection (50–52). For the nasopharyngeal colonization model,
107 CFU of bacteria in 10 l was administered by intranasal inoculation under light halothane general
anesthesia, and nasal washes were obtained after 5 days. Mice were inoculated by intraperitoneal (i.p.)
injection of 5 104 CFU for the sepsis model and by intranasal (i.n.) inoculation under isoflurane
inhalational anesthesia of 5 106 CFU for the pneumonia model. Mice were sacrificed after 24 h (i.p.) or
48 h (i.n.), and serial dilutions of blood and lung homogenates were plated to enumerate target organ
CFU. For the sepsis model, disease development was also monitored by observing mice three times a day
(n 8). For colonization and sepsis competitive infection models, mice were inoculated with a 50/50
ratio of D39 wild type and ΔadcAII strain to determine the competitive index (CI; ratio of mutant to WT
strain recovered from mice divided by the ratio of mutant to WT strain in the inoculum).
Statistical analysis. Statistical analyses were conducted using Prism 7 (Graph Pad, USA). Parametric
data are presented as means, and error bars represent standard deviations. Nonparametric date were
analyzed using the Mann-Whitney U test. For the disease development model, data were analyzed using
the log rank (Mantel-Cox) test.
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